Dementia is a growing public health concern in Canada. This epidemic is linked to huge human and economic costs. The number of Manitobans (65+) with dementia in 2045 (47,021), representing 2.58% of the Manitoban population, will be 2.3 times that of the year 2015 (20,235). The number of cases of dementia in Manitoba grew by 20.7% from 2015 to 2025, 68.16% from 2015 to 2035 and at an alarming rate of 125% from 2015 to 2045. Importantly, the total economic burden of dementia in Manitoba is close to one billion USD and is expected to grow more than 28 billion USD during the year 2038. The focus of this review is to compare dementia rates and the financial burden of dementia in Manitoba with the rest of Canada and the world from 2012 to 2048.

Keywords:
Dementia, Manitoba, Canada, Statistics, Gender, Age, Healthcare costs
1.
Wells CE: Dementia: definition and description. Contemp Neurol Ser 1977; 15: 1–14.
2.
Brayne C, et al: Incidence of clinically diagnosed subtypes of dementia in an elderly population. Cambridge project for later life. Br J Psychiatry 1995; 167: 255–262.
3.
Roman GC, et al: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250–260.
4.
Drachman DA: New criteria for the diagnosis of vascular dementia: do we know enough yet? Neurology 1993; 43: 243–245.
5.
Neary D, Snowden J: Fronto-temporal dementia: nosology, neuropsychology, and neuropathology. Brain Cogn 1996; 31: 176–187.
6.
McKeith IG, et al: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113–1124.
7.
Cummings JL: Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1988; 1: 24–36.
8.
Cummings JL: Treatment of Alzheimer’s disease: current and future therapeutic approaches. Rev Neurol Dis 2004; 1: 60–69.
9.
Cummings JL: Alzheimer’s disease. N Engl J Med 2004; 351: 56–67.
10.
Ferri CP, et al: Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112–2117.
11.
World Health Organization: Dementia: A Public Health Priority, 2012.
12.
International World Health Organization. Alzheimer’s Disease International: Dementia: A Public Health Priority. Mental Health, 2012.
13.
Wimo A, Winblad B, Aguero-Torres H, von Strauss E: The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003; 17: 63–67.
14.
Qiu C, De Ronchi D, Fratiglioni L: The epidemiology of the dementias: an update. Curr Opin Psychiatry 2007; 20: 380–385.
15.
Canadian study of health and aging: study methods and prevalence of dementia. CMAJ 1994; 150: 899–913.
16.
Lindsay JH, Hébert R, Rockwood K: The Canadian study of health and aging: risk factors for vascular dementia. Stroke 1997; 28: 526–530.
17.
Yaffe K, et al: Effect of socioeconomic disparities on incidence of dementia among biracial older adults: prospective study. BMJ 2013; 347:f7051.
18.
Russ TC, Batty GD, Hearnshaw GF, Fenton C, Starr JM: Geographical variation in dementia: systematic review with meta-analysis. Int J Epidemiol 2012; 41: 1012–1032.
19.
Alzheimer Society of Canada: Prevalence and Monetary Costs of Dementia in Canada. Toronto, Alzheimer Society of Canada, 2016.
20.
Savva GM, et al: Age, neuropathology, and dementia. N Engl J Med 2009; 360: 2302–2309.
21.
Sachdev PS, et al: The prevalence of mild cognitive impairment in diverse geographical and ethnocultural regions: the COSMIC collaboration. PLoS One 2015; 10:e0142388.
22.
Smith EE, et al: Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol 2008; 65: 94–100.
23.
Staekenborg SS, et al: Progression of mild cognitive impairment to dementia: contribution of cerebrovascular disease compared with medial temporal lobe atrophy. Stroke 2009; 40: 1269–1274.
24.
Manitoba Centre for Health Policy and Martens P: Patterns of Regional Mental Illness Disorder Diagnoses and Service Use in Manitoba: A Population-Based Study. Winnipeg, Centre for Health Policy, 2004.
25.
Smetanin P, et al: Rising Tide: The Impact of Dementia in Manitoba 2008 to 2038. RiskAnalytica, 2009.
26.
Statistics MB: Population Projection by Sex and Age, 2012–2048, 2015.
27.
Canada S: Aboriginal Peoples: Fact Sheet for Manitoba, 2016.
28.
Naqshbandi M, Harris SB, Esler JG, Antwi-Nsiah F: Global complication rates of type 2 diabetes in Indigenous peoples: a comprehensive -review. Diabetes Res Clin Pract 2008; 82: 1–17.
29.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, et al: Pharmacologic management of type 2 diabetes. Can J Diab 2013; 37(suppl 1):S61–S68.
30.
MacDonald JP, Barnes DE, Middleton LE: Implications of risk factors for Alzheimer’s disease in Canada’s indigenous population. Can Geriatr J 2015; 18: 152–158.
31.
Chappell NL, Hollander MJ: An evidence-based policy prescription for an aging population. Healthc Pap 2011; 11: 8–18.
32.
Browning JS, Schwirian PM: Spousal caregivers’ burden: impact of care recipient health problems and mental status. J Gerontol Nurs 1994; 20: 17–22.
33.
Brodaty H, Donkin M: Family caregivers of people with dementia. Dialogues Clin Neurosci 2009; 11: 217–228.
34.
The Canadian Study of Health and Aging: Risk factors for Alzheimer’s disease in Canada. Neurology 1994; 44: 2073–2080.
35.
Hepburn KW, Tornatore J, Center B, Ostwald SW: Dementia family caregiver training: affecting beliefs about caregiving and caregiver outcomes. J Am Geriatr Soc 2001; 49: 450–457.
36.
Families care: Alzheimer’s Caregiving in the United States. Chicago, Alzheimer’s Association and National Alliance for Caregiving, 2004.
37.
Canada: The Aproaching Tsunami of Alzheimer’s Disease and Dementia, 2013.
38.
Authority WRH, 2015.
39.
Wimo A, et al: The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int J Geriatr Psychiatry 2011; 26: 825–832.
40.
Wimo A, et al: The worldwide economic impact of dementia 2010. Alzheimers Dement 2013; 9: 1–11.e13.
41.
Reports, W. A., 2010.
42.
Wimo A, et al: The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement 2017; 13: 1–7.
43.
Public Health Agency of Canada: Economic Burden of Illness in Canada. 2014, Public Health Agency of Canada, 2005–2008.
44.
Mental Health Commission of Canada: Making the Case for Investing in Mental Health in Canada. Calgary, Mental Health Commission of Canada, 2011.
45.
Public Health Agency of Canada: Economic Burden of Illness in Canada. Ottawa, Public Health Agency of Canada, 2014.
46.
Alzheimer Society of Canada: Rising Tide: The Impact of Dementia on Canadian Society. Toronto, Alzheimer Society of Canada, 2010.
47.
Public Health Agency of Canada: Mapping Connections: An Understanding of Neurological Conditions – The National Population Health Study of Neurological Conditions in Canada Public Health Agency of Canada, 2014.
48.
Statistics, M. B., 2015.
49.
The Canadian study of health and aging: risk factors for Alzheimer’s disease in Canada. Neurology 1994; 44: 2073–2080.
50.
Hebert R, et al: Vascular dementia: incidence and risk factors in the Canadian study of health and aging. Stroke 2000; 31: 1487–1493.
51.
Fratiglioni L, De Ronchi D, Aguero-Torres H: Worldwide prevalence and incidence of dementia. Drugs Aging 1999; 15: 365–375.
52.
Derreberry TM, Holroyd S: Dementia in women. The psychiatric clinics of North America 2017; 40: 299–307.
53.
Brody JA: Prospects for an ageing population. Nature 1985; 315: 463–466.
54.
Monroe RT: The effect of aging of population on general health problems. N Engl J Med 1953; 249: 322–328.
55.
Canada, H., 2011.
56.
Alzheimer’s Association International Conference: New Analysis Shows More Than 28 Million Baby Boomers Will Develop Alzheimer’s Disease; Will Consume Nearly 25% of Medicare Spending, 2015.
57.
Riggs BL, Khosla S, Melton LJ 3rd: A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998; 13: 763–773.
58.
Tiraboschi P, et al: Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 2004; 62: 1977–1983.
59.
Schmechel DE, et al: Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 9649–9653.
60.
Begum AN, et al: Women with the Alzheimer’s risk marker ApoE4 lose Aβ-specific CD4+ T cells 10–20 years before men. Transl Psychiatry 2014; 4:e414.
61.
Genin E, et al: APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011; 16: 903–907.
62.
Hughes TA, et al: A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 2000; 54: 1596–1602.
63.
McKeith IG, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863–1872.
64.
Nelson NW: Differential diagnosis of Alzheimer's dementia and vascular dementia. Dis Mon 2007; 53: 148–151.
65.
Statistics Canada: Aboriginal Peoples in Canada: First Nations People, Métis and Inuit, 2011.
66.
Kramer JH, Duffy JM: Aphasia, apraxia, and agnosia in the diagnosis of dementia. Dementia 1996; 7: 23–26.
67.
Henderson JN, Traphagan JW: Cultural factors in dementia: perspectives from the anthropology of aging. Alzheimer Dis Assoc Disord 200; 19: 272–274.
68.
Jacklin KM, Walker JD, Shawande M: The emergence of dementia as a health concern among First Nations populations in Alberta, Canada. Can J Public health 2012; 104:e39–e44.
69.
Strachan MW, Deary IJ, Ewing FM, Frier BM: Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 1997; 20: 438–445.
70.
Canadian Diabetes Association: Diabetes in Canada, 2016.
71.
Canadian Diabetes Association: Diabetes in Manitoba, 2016.
72.
Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R: Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154: 635–641.
73.
Schnaider Beeri M, et al: Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 2004; 63: 1902–1907.
74.
Leibson CL, et al: The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann N Y Acad Sci 1997; 826: 422–427.
75.
Yaffe K, et al: Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004; 63: 658–663.
76.
Rasgon NL, et al: Insulin resistance and hippocampal volume in women at risk for Alzheimer’s disease. Neurobiol Aging 2011; 32: 1942–1948.
77.
Talbot K, et al: Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122: 1316–1338.
78.
Haroon NN, et al: Risk of dementia in seniors with newly diagnosed diabetes: a population-based study. Diabetes Care 2015; 38: 1868–1875.
79.
Luchsinger JA, Patel B, Tang MX, Schupf N, Mayeux R: Measures of adiposity and dementia risk in elderly persons. Arch Neurol 2007; 64: 392–398.
80.
Beydoun MA, et al: Association of adiposity status and changes in early to mid-adulthood with incidence of Alzheimer’s disease. Am J Epidemiol 2008; 168: 1179–1189.
81.
Kivipelto M, et al: Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447–1451.
82.
Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K: Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med 2004; 164: 1327–1333.
83.
Peila R, Rodriguez BL, Launer LJ; Honolulu-Asia Aging Study: Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia aging study. Diabetes 2002; 51: 1256–1262.
84.
Allen KV, Frier BM, Strachan MW: The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 2004; 490: 169–175.
85.
Awad N, Gagnon M, Messier C: The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol 2004; 26: 1044–1080.
86.
Nielson KA, et al: Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer’s disease? J Am Geriatr Soc 1996; 44: 897–904.
87.
Bucht G, Adolfsson R, Lithner F, Winblad B: Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. Acta Med Scand 1983; 213: 387–392.
88.
Wolf H, Gertz HJ: [Vascular dementia – diagnosis, prevention and treatment]. Psychiatr Prax 2004; 31: 330–338.
89.
McVeigh C, Passmore P: Vascular dementia: prevention and treatment. Clin Intervent Aging 2006; 1: 229–235.
90.
MacKnight C, Rockwood K, Awalt E, McDowell I: Diabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian study of health and aging. Dement Geriatr Cogn Disord 2002; 14: 77–83.
91.
Hassing LB, et al: Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest old. Int Psychogeriatr 2002; 14: 239–248.
92.
Ott A, et al: Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 1999; 53: 1937–1942.
93.
Leibson CL, et al: Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997; 145: 301–308.
94.
Moreira PI: High-sugar diets, type 2 diabetes and Alzheimer’s disease. Curr Opin Clin Nutr Metab Care 2013; 16: 440–445.
95.
Ravona-Springer R, et al: Diabetes is associated with increased rate of cognitive decline in questionably demented elderly. Dement Geriatr Cogn Disord 2010; 29: 68–74.
96.
Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782–787.
97.
Alzheimer Society Report: Dementia numbers in Canada, 2015.
98.
World Health Organization: Dementia, 2016.
99.
Public Health Agency of Canada: Mapping Connections: An Understanding of Neurological Conditions in Canada-The National Population Health Study of Neurological Conditions. Ottawa, Public Health Agency of Canada, 2014.
100.
Alzheimer Society of Canada: Revised Dementia Statistics (Rising Tide 2.0). Toronto, Alzheimer Society of Canada, 2012.
101.
Alzheimer Society of Canada: Prevalence and Monetary Costs of Dementia in Canada. Toronto, Alzheimer Society of Canada, 2016.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.